BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ATSConferenceNews.org - ECPv6.3.4//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:ATSConferenceNews.org X-ORIGINAL-URL:https://www.atsconferencenews.org X-WR-CALDESC:Events for ATSConferenceNews.org REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240519T113000 DTEND;TZID=America/Los_Angeles:20240519T120000 DTSTAMP:20240328T161642 CREATED:20240315T211027Z LAST-MODIFIED:20240321T193553Z UID:10000221-1716118200-1716120000@www.atsconferencenews.org SUMMARY:When It Could Be Cystic Fibrosis (CF): Diagnosing CF in People with Atypical Disease Presentation DESCRIPTION:Innovation Theater 1Supported By: Vertex Pharmaceuticals Inc. \n\n\n\n\n\n\n\nProgram Description \n\n\n\nThe face of CF has changed considerably over the last few decades. This session sponsored by Vertex Pharmaceuticals Inc. will focus on atypical presentation of CF. This session will highlight the importance of recognizing unique signs and symptoms in adults and diagnosing CF with sweat chloride and genetics. \n\n\n\nAn Industry Theater presentation at the ATS 2024 International Conference. This presentation is sponsored by Vertex and is open to all ATS 2024 International Conference attendees \n\n\n\nSpeakers \n\n\n\nPresenter: Susanna A. McColley\, MD\, FAAP\, ATSF Northwestern University Feinberg School of MedicineProfessor of Pediatrics in Pulmonary and Sleep MedicineChicago\, IllinoisStanley Manne Children’s Research Institute\, Anne & Robert H. Lurie Children’s Hospital of ChicagoScientific Director for Interdisciplinary Research PartnershipsChicago\, Illinois URL:https://www.atsconferencenews.org/event/sl000023609/ CATEGORIES:Innovation Hubs END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240519T113000 DTEND;TZID=America/Los_Angeles:20240519T123000 DTSTAMP:20240328T161642 CREATED:20240326T214951Z LAST-MODIFIED:20240327T152711Z UID:10000223-1716118200-1716121800@www.atsconferencenews.org SUMMARY:Clinical and patient-centered discussions on the role of inflammation in bronchiectasis DESCRIPTION:Innovation Theater 5Supported By: Insmed \n\n\n\n\n\n\n\nProgram Description \n\n\n\nJoin Insmed for an Industry Theater presentation to learn more about bronchiectasis exacerbations and their management. Lunch will be provided. While bronchiectasis is often identified in patients with other lung diseases like COPD and asthma\, it is a separate chronic lung disease usually marked by permanent\, abnormal dilation and persistent inflammation of the airways. Patients with bronchiectasis often suffer from periods of worsening symptoms\, or exacerbations\, which can damage the lungs and contribute to the burden of the disease\, affecting health-related quality of life. \n\n\n\nIn scientific literature\, bronchiectasis has been characterized as a vicious cycle or vortex consisting of 4 primary drivers: chronic airway inflammation\, impaired mucociliary clearance\, lung destruction\, and chronic airway infection. The role of inflammation in driving this condition continues to be a subject of research\, with increasing evidence implicating neutrophilic inflammation in perpetuating the vicious vortex and contributing to recurrent damaging bronchiectasis exacerbations. \n\n\n\nDuring this presentation\, participants will explore the burdens and underlying causes of bronchiectasis exacerbations\, with a particular focus on potential management strategies. This session will also delve into the key drivers of bronchiectasis\, highlighting the critical role of inflammation in disease progression. Bronchiectasis experts will lead participants on a journey into the functions of the neutrophil\, emphasizing how the mechanisms intended to defend against infection can\, instead\, be destructive during bronchiectasis. They will review data linking the inflammatory process to bronchiectasis exacerbations and worse clinical outcomes for patients with this disease. \n\n\n\nTo learn more about bronchiectasis and bronchiectasis exacerbations\, join Insmed in the Exhibit Hall at Booth #2343. We are offering a variety of resources and events this year\, including an immersive exhibit featuring bronchiectasis research\, a 3D lung model\, interactive explorations of the science\, and more. \n\n\n\nNP-BE-US-00433 \n\n\n\nSpeakers \n\n\n\nPanelist: George M. Solomon\, MD\, UAB Division of Pulmonary\, Allergy\, and Critical Care Medicine. Director\, UAB Adult PCD and Bronchiectasis ProgramsUniversity of Alabama at BirminghamBirmingham\, Alabama \n\n\n\nPanelist: Colin Swenson\, MDSection Chief\, Pulmonary and Critical CareDirector\, NCFB/NTM ProgramEmory Healthcare URL:https://www.atsconferencenews.org/event/sl000023124/ CATEGORIES:Industry Theater END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240519T133500 DTEND;TZID=America/Los_Angeles:20240519T135500 DTSTAMP:20240328T161642 CREATED:20240308T153142Z LAST-MODIFIED:20240322T191532Z UID:10000219-1716125700-1716126900@www.atsconferencenews.org SUMMARY:Tools of the Trade: Imaging in ILD DESCRIPTION:Innovation Hub #3Supported By: Boehringer Ingelheim Pharmaceuticals\, Inc. \n\n\n\n\n\n\n\nProgram Description \n\n\n\nJoin Dr. Jonathan Chung\, a cardiothoracic radiologist from the University of California\, San Diego\, as he showcases two useful tools for improving recognition of interstitial lung disease on HRCT scans. \n\n\n\nThe Imaging Atlas of Interstitial Lung Diseases is a comprehensive digital and print resource that aids clinicians in identifying lesions consistent with infiltrative lung disease and characteristic aspects of ILDs. This collection has detailed CT and numerous histopathology sections\, and it can assist clinicians in recognizing specific ILD-associated markers throughout diagnostic process. \n\n\n\nThe Rad Rounds – UIP to IPF App is an easy to use\, peer-reviewed app that provides healthcare practitioners with visual references for recognizing and evaluating usual interstitial pneumonia (UIP) and ILDs on HRCT. \n\n\n\nAn Innovation Hub presentation at the ATS 2024 International Conference. This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals\, Inc. and is open to all ATS 2024 International Conference attendees. \n\n\n\nThis is a non-CME event and does not qualify for CME or CE credit. Onsite registration/admission will occur for conference registrants only at the industry theater entrance\, on a first-come\, first-serve basis. \n\n\n\nPresentation content has been reviewed for consistency with FDA guidelines and is not approved for continuing medical education credit. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals\, attendance at this promotional program is limited to healthcare professionals\, attendance by healthcare professionals’ spouses or guests is not permitted. \n\n\n\nSpeakers \n\n\n\nPresenter: Jonathan H. Chung\, MDUniversity of CaliforniaCardiothoracic Imaging Division Chief San Diego\, California URL:https://www.atsconferencenews.org/event/sl000023164/ CATEGORIES:Industry Theater END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240520T113000 DTEND;TZID=America/Los_Angeles:20240520T123000 DTSTAMP:20240328T161642 CREATED:20240308T215545Z LAST-MODIFIED:20240322T143153Z UID:10000220-1716204600-1716208200@www.atsconferencenews.org SUMMARY:Interstitial Lung Disease: Presentation to Patient Experience DESCRIPTION:Innovation Theater 5Supported By: Boehringer Ingelheim Pharmaceuticals\, Inc. \n\n\n\n\n\n\n\nProgram Description \n\n\n\nPlease join expert pulmonologist Tanzira Zaman\, MD as she presents case studies of interstitial lung disease (ILD) and discusses the real-life impact of ILD with a patient mentor. Dr. Zaman will review the signs and symptoms in several hypothetical cases\, then engage in a conversation with Brittany R.\, a real-life patient\, to discuss the diagnostic journey and challenges of living with ILD. \n\n\n\nThis presentation will emphasize the importance of the relationships between clinicians and their patients\, as well as the necessity of a multidisciplinary approach to co-managing ILD. \n\n\n\nAn Industry Program presentation at the ATS 2024 International Conference.This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals\, Inc. and is open to all ATS 2024 International Conference attendees. \n\n\n\nThis is a non-CME event and does not qualify for CME or CE credit. Onsite registration/admission will occur for conference registrants only at the industry theater entrance\, on a first-come\, first-serve basis. \n\n\n\nPresentation content has been reviewed for consistency with FDA guidelines and is not approved for continuing medical education credit. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals\, attendance at this promotional program is limited to healthcare professionals\, attendance by healthcare professionals’ spouses or guests is not permitted. \n\n\n\nSpeakers \n\n\n\nPresenter: Tanzira Zaman\, MDCedars-Sinai Medical CenterInterstitial Lung Disease\, Medical DirectorPulmonary & Critical Care Fellowship\, Associate Program DirectorLos Angeles\, California URL:https://www.atsconferencenews.org/event/sl000023162/ CATEGORIES:Industry Theater END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240520T183000 DTEND;TZID=America/Los_Angeles:20240520T203000 DTSTAMP:20240328T161642 CREATED:20230327T190819Z LAST-MODIFIED:20240314T164411Z UID:10000157-1716229800-1716237000@www.atsconferencenews.org SUMMARY:Exploring the Impact of OFEV® (nintedanib) capsules DESCRIPTION:Marriott Marquis\, Marina Ballroom F/GSupported By: Boehringer Ingelheim Pharmaceuticals\, Inc. \n\n\n\n\n\n\n\nProgram Description \n\n\n\nAt this non-CME educational event\, Dr. Cedric “Jamie” Rutland will explore the use of OFEV® (nintedanib) capsules\, while emphasizing the importance of patient-centered care through the narrative of a patient mentor. The audience will gain insights into the pharmacology of OFEV\, and Dr. Rutland will highlight key efficacy and safety data. Before the clinical data is presented\, Sylvia R.\, a patient mentor\, will share their personal journey and provide a firsthand account of their treatment with OFEV\, offering a real-world perspective on the impact of OFEV. \n\n\n\nAn Industry Supported Symposium at the ATS 2024 International Conference. This evening educational program is sponsored by Boehringer Ingelheim Pharmaceuticals\, Inc. open to all ATS 2024 International Conference attendees. \n\n\n\nThis is a non-CME event and does not qualify for CME or CE credit. Onsite registration/admission will occur for conference registrants only at the symposium entrance\, on a first-come\, first-serve basis. \n\n\n\nPresentation content has been reviewed for consistency with FDA guidelines and is not approved for continuing medical education credit. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals\, attendance at this promotional program is limited to healthcare professionals\, attendance by healthcare professionals’ spouses or guests is not permitted. \n\n\n\nSpeakers \n\n\n\nPresenter: Cedric “Jamie” Rutland\, MDRutland Medical GroupPulmonary and Critical Care PhysicianCEO and Medical DirectorRiverside\, California URL:https://www.atsconferencenews.org/event/sl000023163/ CATEGORIES:Evening Symposium END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240521T120000 DTEND;TZID=America/Los_Angeles:20240521T123000 DTSTAMP:20240328T161642 CREATED:20240326T211330Z LAST-MODIFIED:20240326T211651Z UID:10000222-1716292800-1716294600@www.atsconferencenews.org SUMMARY:Holistic Care of the Immunocompromised Pulmonary Patient with EGPA DESCRIPTION:Innovation Theater 2Supported By: GSK \n\n\n\n\n\n\n\nProgram Description \n\n\n\nPatients with pulmonary conditions (e.g. asthma\, chronic bronchitis\, EGPA) can be immunocompromised due to their diseases or treatments. Identifying and managing the immunocompromised pulmonary patient can be challenging and complex. Interact with an expert pulmonologist and a professor of public health as they discuss a holistic approach to managing these patients through a case discussion of a pulmonary patient with EGPA. \n\n\n\nAn Industry Theater presentation at the ATS 2024 International Conference. This presentation is sponsored by GSK. Due to regulatory restrictions\, this presentation is only available to attendees from the United States. This information is scientific and non-promotional in nature. \n\n\n\nSpeakers \n\n\n\nPresenter: Kevin Winthrop\, MD\, MPHOregon Health & Science UniversityInfectious Disease and OpthamologyProfessorPortland\, Oregon \n\n\n\nOHSU-PSUSchool of Public HealthProfessorPortland\, Oregon \n\n\n\nPresenter: Michael Wechsler\, MDNational Jewish HealthCohen Family Asthma InstituteDivision of Pulmonary\, Critical Care & Sleep MedicinePulmonologistDenver\, Colorado \n\n\n\nCohen Family Asthma InstituteDirectorDenver\, Colorado URL:https://www.atsconferencenews.org/event/sl000023634/ CATEGORIES:Industry Theater END:VEVENT END:VCALENDAR